Research analysts at Wedbush lowered their Q1 2025 EPS estimates for Travere Therapeutics in a report released on Monday, February 24th. Wedbush analyst L. Chico now expects that the company will post ...
Wedbush raised the firm’s price target on Janux Therapeutics (JANX) to $76 from $75 and keeps an Outperform rating on the shares following ...
As mentioned, Palantir has declined 32% from its record high in the last seven trading days, but the statistics suggest the ...
Equities researchers at Wedbush raised their FY2024 earnings estimates for shares of Playtika in a report issued on Wednesday, February 26th. Wedbush analyst M. Pachter now forecasts that the company ...
Wedbush analyst Matt Bryson lowered the firm’s price target on NetApp (NTAP) to $110 from $120 and keeps a Neutral rating on the shares. After ...
Wedbush Securites, a 70-year-old financial services firm based in Los Angeles, has filed with the Securities and Exchange ...
Wedbush made a splash on Tuesday with the announcement that it was entering the ever-growing exchange-traded fund market. With more than 7K ETFs listed globally, collectively managing over $10T in ...
But now there is one analyst who’s again projecting upside: Wedbush’s Daniel Ives boosted his target price to $90 on Thursday morning. Palantir’s stock PLTR closed at $76.87 on Wednesday ...
AI spending is ramping up, with Nvidia (NVDA) seeing strong Blackwell demand and IT budgets shifting toward AI investments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback